|
Market Closed -
Nasdaq
16:00:00 2026-10-06 EDT
|
5-day change | 1st Jan Change | ||
| 119.57 USD | -2.02% |
|
+4.21% | +243.59% |
| Market Cap | 12.93B 11.47B 10.74B 9.73B 18.38B 1,246B 18.51B 129B 50.16B 636B 48.52B 47.48B 2,043B | P/E 2026 * |
58x | P/E 2027 * | 27.9x |
|---|---|---|---|---|---|
| Enterprise Value | 12.93B 11.47B 10.74B 9.73B 18.38B 1,246B 18.51B 129B 50.16B 636B 48.52B 47.48B 2,043B | EV / Sales 2026 * |
11.3x | EV / Sales 2027 * | 7.58x |
| Free-Float |
65.9% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| CORT | Delayed | |
CBOE
| CORT | Real-time | |
|
Tradegate
| HTD | Real-time | |
|
Boerse Muenchen
| HTD | Real-time | |
|
London S.E.
| 0I3Q | Delayed | |
|
Deutsche Boerse AG
| HTD | Delayed | |
|
Börse Stuttgart
| HTD | Delayed | |
|
Berne S.E.
| HTD | End-of-day quote | |
|
Borsa Italiana
| 1CORT | End-of-day quote |
Last Transcript: Corcept Therapeutics Incorporated
| 1 day | -2.02% | ||
| 1 week | +4.21% | ||
| Current month | +3.77% | ||
| 1 month | +7.12% | ||
| 3 months | +30.52% | ||
| 6 months | +192.71% | ||
| Current year | +243.59% |
| 1 week | 111.94 |  | 122.81 |
| 1 month | 108.25 | | 122.81 |
| Current year | 28.66 | | 126.38 |
| 1 year | 28.66 | | 126.38 |
| 3 years | 20.84 | | 126.38 |
| 5 years | 15.82 | | 126.38 |
| 10 years | 6.11 | | 126.38 |
| Manager | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
CEO | Chief Executive Officer | 68 | 1998-12-31 |
Atabak Mokari
DFI | Director of Finance/CFO | 49 | 2021-02-28 |
Joseph Lyon
CTO | Chief Tech/Sci/R&D Officer | 48 | 2024-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
BRD | Director/Board Member | 68 | 1998-12-31 |
James Wilson
CHM | Chairman | 82 | 1998-12-31 |
David Mahoney
BRD | Director/Board Member | 71 | 2004-06-30 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/24/26 | Don | Company Secretary | -27,100 | 0.0251% | ||
| 9/17/26 | Exercice | Company Secretary | 34,986 | 0.0324% | ||
| 9/16/26 | Sell | President, Oncology | -296 | 0.0003% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.02% | +4.21% | +33.08% | +352.92% | 13.19B | |
| +1.26% | -2.29% | +36.97% | +104.79% | 1,019B | |
| +0.73% | -4.78% | +35.41% | +61.62% | 610B | |
| +0.35% | +1.29% | +15.86% | +79.90% | 470B | |
| +1.72% | -4.92% | +59.84% | +36.64% | 344B | |
| +0.26% | -1.58% | +21.97% | +41.79% | 336B | |
| +0.60% | -3.48% | +11.37% | +34.33% | 266B | |
| +1.65% | -4.27% | -5.47% | +9.69% | 241B | |
| -0.09% | -4.97% | +36.88% | +50.52% | 218B | |
| -0.28% | -4.66% | +26.99% | +92.98% | 179B | |
| Average | +0.14% | -2.79% | +27.29% | +86.52% | 369.6B | |
| Weighted average by Cap. | +0.05% | -3.40% | +29.68% | +68.27% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.15B 1.02B 952M 863M 1.63B 110B 1.64B 11.44B 4.45B 56.36B 4.3B 4.21B 181B | 1.7B 1.51B 1.42B 1.28B 2.42B 164B 2.44B 17.01B 6.62B 83.84B 6.4B 6.26B 270B |
| Net income | 242M 214M 201M 182M 343M 23.28B 346M 2.41B 937M 11.88B 907M 887M 38.19B | 594M 527M 493M 447M 844M 57.22B 850M 5.92B 2.3B 29.19B 2.23B 2.18B 93.85B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-06 | US$119.57 | -2.02% | 786,536 |
| 26-10-05 | US$122.03 | +4.99% | 1,004,939 |
| 26-10-02 | US$116.23 | +1.93% | 960,161 |
| 26-10-01 | US$114.03 | -1.05% | 878,988 |
| 26-09-30 | US$115.23 | +0.43% | 910,311 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CORT Stock
Select your edition
All financial news and data tailored to specific country editions
